Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,440.42
(
1.52%
)
US TECH 100
22,714.40
(
1.72%
)
Dow Jones
45,722.46
(
1.12%
)
Brent Oil
107.02
(
-1.43%
)
Bitcoin
66,997.20
(
0.44%
)
News Focus
News Focus
Post# of 257320
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122828
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dink00 post# 107023

Friday, 10/22/2010 5:54:34 PM

Friday, October 22, 2010 5:54:34 PM

Post# of 257320

…but I doubt if NVS shareholder feels the same way.

I strongly disagree. By any objective measure, the NVS-MNTA 2003 collaboration to develop Lovenox for the US market has superb terms for NVS. So much so that Craig Wheeler and Rick Shea can often be heard on investor webcasts sheepishly apologizing for the Lovenox deal terms and reminding investors that MNTA negotiated a better deal for Copaxone.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today